Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
24 Aug 25
Updated
24 Aug 25
AnalystLowTarget's Fair Value
€524.73
12.4% overvalued intrinsic discount24 Aug
€590.00
1Y
26.3%7D
2.9%1Y
26.3%7D
2.9%